BioPharma Today

Coming In Monday's "The Pink Sheet" DAILY - Tracking Biomedical Innovation Is Concern For Stakeholders

Financings of the fortnight ponders whether mapping the microbiome holds the key to future drugs and diagnostics. Plus news on recent financial activity by Tesaro, Omeros, Neviah Genomics and Aegerion Pharmaceuticals.

Latest News From "The Pink Sheet" DAILY - States May Reject Medicaid Expansion Without Penalties Under Supreme Court Ruling

Supreme Court Ruling Retains Rx Provisions But May Have Pharma Re-Counting Customers The Supreme Court upholds most of the Affordable Care Act as constitutional, but limits the federal government's ability to withhold payments to induce states to expand eligibility for their Medicaid programs.

Editor's Picks From The World Press

Business & Finance

Arena's Belviq might spur Big Pharma to enter obesity market
Bloomberg Businessweek Jun. 28, 2012

Coming in Friday's "The Pink Sheet" DAILY

Medicaid rebate increase, Medicare Part D discounts, annual pharma industry fees retained In Supreme Court ruling on the Affordable Care Act.

Latest News From "The Pink Sheet" DAILY - AstraZeneca, Merck Renew Agreement For Acid Reflux Medicines

Belviq Gains FDA Approval For Weight Loss, But DEA Review Will Delay Launch With a July 17 user fee date, Vivus' obesity drug Qnexa could beat Arena Pharmaceuticals' Belviq to the marketplace as lorcaserin awaits controlled substance scheduling by the Drug Enforcement Agency.

Editor's Picks from the World Press

Business & Finance

Patheon will manufacture Adventrx drug for clinical study
Pharmaceutical Business Review Online Jun. 27, 2012

Coming In Thursday's "The Pink Sheet" DAILY - Arena Gets Obesity Drug Approval

Arena Pharmaceuticals received FDA approval June 27 for the company’s weight-loss drug  Belviq (lorcaserin) for use by patients who are obese or who are overweight and have at least one weight-related co-morbidity.

Latest News From "The Pink Sheet" DAILY - Roche To Leave Former NJ Headquarters

Roche Shakes Up R&D, Closes Nutley Operations Roche will shut down its Nutley, N.J., pharma operations - once its U.S. headquarters - by the end of 2013 in a cost-saving measure that will leave only a small group of employees on the East Coast.

Editor's Picks From The World Press

Business & Finance

40% gain is likely for Onyx after regulatory support for carfilzomib
American City Business Journals Jun. 26, 2012

5 large drugmakers reportedly prepare final offers for Amylin
Reuters Jun. 26, 2012

TaiGen signs 20-year antibiotic deal with Zhejiang Medicine
The Taipei Times (Taiwan) Jun. 26, 2012

Government & Legal News

Senate passes legislation to let FDA collect $6B in user fees
The Wall Street Journal Jun. 26, 2012

Supernus' epilepsy drug Trokendi XR gains tentative FDA approval
MarketWatch Jun. 26, 2012

FDA warns against cefepime's inappropriate dose in renal impairment
Medscape (free registration) Jun. 26, 2012

Watchdog calls for FDA rejection of Arena's diet pill lorcaserin
Reuters Jun. 26, 2012

India eyes price revision for 50 medicines
The Economic Times (India) Jun. 26, 2012

Pipeline/R&D News

TPA shows no risk for stroke patients on warfarin in study
MedPage Today Jun. 26, 2012

Millennium's Velcade works against refractory SLE in study
InternalMedicineNews.com Jun. 26, 2012

Alzheimer's drug memantine reduces compulsive buying in study
Medscape (free registration) Jun. 26, 2012

Statins work better for men than women, study finds
Reuters Jun. 25, 2012

Coming In Wednesday's "The Pink Sheet" DAILY - Roche To Close Nutley Pharma Operations

Roche will shut down its Nutley, NJ pharma operations – once its U.S. headquarters – by the end of 2013 in a cost-saving measure that will leave only a small group of employees on the East Coast.